MedTrace Logo

Phase 1 Study of ADX-626 in Healthy Participants

NCT07081503 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-03-02

No results posted yet for this study

Summary

This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).

Conditions

  • Healthy Adult Participants

Interventions

DRUG

ADX-626

siRNA duplex oligonucleotide

DRUG

Placebo

Saline

Sponsors & Collaborators

  • ADARx Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Aditya Patel, MD · ADARx Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-12
Primary Completion
2027-01-22
Completion
2027-01-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07081503 on ClinicalTrials.gov